Email this article Adjuvant hormone therapy for improvement of disease control in patients with non-metastatic prostate cancer with poor prognosis
- Authors: Fleshner N.1, Keane T.E.2, Lawton C.A.3, Mulders P.F.4, Payne H.5, Taneja S.S.6, Morris T.7
-
Affiliations:
- Princess Margaret Hospital, Toronto, Ontario
- Medical University of South Carolina, Charleston, SC
- Medical College of Wisconsin, Milwaukee, WI
- University Hospital Nijmegen, Nijmegen
- Meyerstein Institute of Oncology, Middlesex Hospital, London
- New York University School of Medicine, New York, NY
- AstraZeneca, Alderley Park, Macclesfield
- Issue: Vol 4, No 3 (2008)
- Pages: 66
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER
- Published: 30.09.2008
- URL: https://oncourology.abvpress.ru/oncur/article/view/1071
- DOI: https://doi.org/10.17650/1726-9776-2008-4-3-66
- ID: 1071
Cite item
Full Text
Abstract
About the authors
N. Fleshner
Princess Margaret Hospital, Toronto, Ontario
Author for correspondence.
Division of Urology Canada
T. E. Keane
Medical University of South Carolina, Charleston, SCUnited States
C. A. Lawton
Medical College of Wisconsin, Milwaukee, WIUnited States
P. F. Mulders
University Hospital Nijmegen, NijmegenNetherlands
H. Payne
Meyerstein Institute of Oncology, Middlesex Hospital, LondonUnited Kingdom
S. S. Taneja
New York University School of Medicine, New York, NYUnited States
T. Morris
AstraZeneca, Alderley Park, MacclesfieldUnited Kingdom
References
Supplementary files
